You are here: Industry Insights > Biohaven

News List

Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine ExpressPharma
February 15, 2022
This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific.
Biohaven Appoints Chairman and CFO contractpharma
December 07, 2021
Vlad Coric to serve as Chairman and Matthew Buten as Chief Financial Officer.
Biohaven Appoints Kishen Mehta to Board of Directors firstwordpharma
June 18, 2021
Biohaven Pharmaceutical Holding Company Ltd. today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board"). Mr. Mehta previously served as a strategic advisor to Biohaven.
FDA Approves Biohaven's NURTEC® ODT: First and Only Migraine Medication for both Acute and Preventive Treatment americanpharmaceuticalreview
June 02, 2021
Biohaven Pharmaceutical Holding Company announced that the U.S. FDA has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine.
Biohaven Provides Update on Phase 2/3 Trial, Alzheimer's Program americanpharmaceuticalreview
January 20, 2021
Biohaven Pharmaceutical has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD).
Biohaven Begins Phase 3 Troriluzole Trial for Obsessive-Compulsive Disorder americanpharmaceuticalreview
January 11, 2021
Biohaven has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD).
Biohaven Acquires Remaining Stake in Kleo Pharmaceuticals contractpharma
January 11, 2021
Enters exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from Spiegel Lab.
Zavegepant Receives Authorization to Proceed, Achieves First In Human Dosing americanpharmaceuticalreview
September 17, 2020
Biohaven Pharmaceutical reported the U.S. Food and Drug Administration (FDA) has authorized the initiation of clinical trials for oral zavegepant (formerly BHV-3500) and the company has achieved first in human dosing in a Phase 1 trial designed to ...
Biohaven's Verdiperstat Receives Fast Track Designation for Multiple System Atrophy Treatment americanpharmaceuticalreview
March 19, 2020
Biohaven Pharmaceutical announced the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, received Fast Track designation from the US Food and Drug Administration (FDA) ...
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment americanpharmaceuticalreview
March 18, 2020
Catalent welcomed the announcement by Biohaven the U.S. Food and Drug Administration (FDA) has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.

Previous page 1 2 3 4 Next page